An interesting point is that, according to studies, rapamycin can potentiate the anticancer properties that doxorubicin has and, when combined, can inhibit cancer cell growth and lead to cell death by impacting mTOR/p70S6K signalling [87]. The gene discussed is MTOR; the disease is cancer.